User Settings
Article10.1161/circ.124.suppl_21.a9426

Abstract 9426: Is Aspirin Beneficial for Primary Prevention of Cardiovascular Events in High-Risk Diabetic Patients? -Insights from the JPAD Trial

Sadanori Okada,Takeshi Morimoto,Hisao Ogawa,Mio Sakuma,Hirofumi Soejima,Masafumi Nakayama+10 more-2011-11-22-Circulation
0

TL;DRAbstract

Benefit of low-dose aspirin for primary prevention of cardiovascular events remains controversial in diabetic patients. Recently, the ADA, AHA and ACCF jointly recommended that low-dose aspirin use is reasonable for high-risk diabetic patients: older patients with additional cardiovascular risk factors. Thus, we evaluated aspirin's benefit in diabetic patients stratified by cardiovascular risk factors in the JPAD trial. This study is a subanalysis of the JPAD trial: a randomized, controlled trial to assess whether low-dose aspirin reduced cardiovascular events in patients with type 2 diabetes and no history of cardiovascular disease. We randomly assigned 2,539 patients to the aspirin group (81 or 100 mg daily) or the no aspirin group, and followed for 4.4 years. We classified all participants into four subgroups according to the following risk stratification: age (men, >50 or ≤50 years; women, >60 or ≤60 years) and one or more additional risk factors (smoking, hypertension, dysli

Chat with Paper

AI Agents for this Paper

Benefit of low-dose aspirin for primary prevention of cardiovascular events remains controversial in diabetic patients. Recently, the ADA, AHA and ACCF jointly recommended that low-dose aspirin use is reasonable for high-risk diabetic patients: older patients with additional cardiovascular risk factors. Thus, we evaluated aspirin's benefit in diabetic patients stratified by cardiovascular risk factors in the JPAD trial. This study is a subanalysis of the JPAD trial: a randomized, controlled trial to assess whether low-dose aspirin reduced cardiovascular events in patients with type 2 diabetes and no history of cardiovascular disease. We randomly assigned 2,539 patients to the aspirin group (81 or 100 mg daily) or the no aspirin group, and followed for 4.4 years. We classified all participants into four subgroups according to the following risk stratification: age (men, >50 or ≤50 years; women, >60 or ≤60 years) and one or more additional risk factors (smoking, hypertension, dysli

Keywords

MedicineAspirinPrimary preventionDiabetes mellitusIntensive care medicineInternal medicineDiseaseEndocrinology

Chat

Click to start Chat